Significância clinicopatológica e prognóstica da COX-2 em pacientes com glioma: uma metanálise

Wang, Jun; Xiang, Chenyan; Cai, Yi; Mei, Ziyi; Lu, Qianqian; Liu, Binbin; Zou, Lili

Jun Wang

contributed to the intellectual content of the present paper

made significant contributions to the conception

design

acquisition of data

analysis

interpretation of data

contributed to drafting

revising the article for intellectual content

approved the final version submitted for publication

China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.

https://orcid.org/0000-0003-2343-4381

Chenyan Xiang

contributed to the intellectual content of the present paper

made significant contributions to the conception

design

acquisition of data

analysis

interpretation of data

contributed to drafting

revising the article for intellectual content

approved the final version submitted for publication

China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.

https://orcid.org/0000-0003-4304-1753

Yi Cai

contributed to the intellectual content of the present paper

made significant contributions to the conception

design

acquisition of data

analysis

interpretation of data

contributed to drafting

revising the article for intellectual content

approved the final version submitted for publication

China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.

China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.

https://orcid.org/0000-0002-0200-7009

Ziyi Mei

contributed to the intellectual content of the present paper

made significant contributions to the conception

design

acquisition of data

analysis

interpretation of data

contributed to drafting

revising the article for intellectual content

approved the final version submitted for publication

China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.

China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.

https://orcid.org/0000-0002-6539-8465

Qianqian Lu

contributed to the intellectual content of the present paper

made significant contributions to the conception

design

acquisition of data

analysis

interpretation of data

contributed to drafting

revising the article for intellectual content

approved the final version submitted for publication

China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.

China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.

https://orcid.org/0000-0001-6138-9847

Binbin Liu

contributed to the intellectual content of the present paper

made significant contributions to the conception

design

acquisition of data

analysis

interpretation of data

contributed to drafting

revising the article for intellectual content

approved the final version submitted for publication

China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.

China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.

https://orcid.org/0000-0001-8003-9359

Lili Zou Address for correspondence Lili Zou (e-mail: zoulili@ctgu.edu.cn).

contributed to the intellectual content of the present paper

made significant contributions to the conception

design

acquisition of data

analysis

interpretation of data

contributed to drafting

revising the article for intellectual content

approved the final version submitted for publication

China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.

China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.

https://orcid.org/0000-0003-1393-0971

Address for correspondence Lili Zou (e-mail: zoulili@ctgu.edu.cn).

Conflict of Interest

The authors have no conflict of interests to declare.

Study ID	Country	Patients	Histology	Grade	Method	Outcomes	Confounding factors	Quality
Shono et al. (2001)³⁷37 Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001;61(11):4375–4381	United States	66	Glioma	Not available	Immunohistochemistry	Overall survival	Age, histology, MIB-1, p53, Rb, and BCL2	7
Castilla et al. (2003)³⁸38 Castilla EA, Prayson RA, Kanner AA, et al. Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 2003;98(07):1465–1472. Doi: 10.1002/cncr.11632 https://doi.org/10.1002/cncr.11632...	United Sates	60	Glioma	II-III	Immunohistochemistry	Overall survival	None	6
Lee et al. (2004)³⁹39 Lee M-C, et al. Cyclooxygenase-2 expression predicts prognosis in astrocytic tumors. J Korean Neurosurg Soc 2004;36(06):437–442	Korea	25	Glioma	Not available	Immunohistochemistry	Overall survival	None	6
Buccoliero et al. (2004)⁴⁰40 Buccoliero AM, Caldarella A, Arganini L, et al. Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance. Neuropathology 2004;24(03):201–207	Italy	34	Glioma	II-IV	Immunohistochemistry	Median survival	None	4
Perdiki et al. (2007)⁴¹41 Perdiki M, Korkolopoulou P, Thymara I, et al. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem 2007;295(1-2):75–83	Greece	83	Astrocytomas	II-IV	Immunohistochemistry	Overall survival/hazard ratio	Age, WHO grade, gender, VEGF, HIF-1α, MVD, TVA	7
Onguru et al. (2008)⁴²42 Onguru O, Gamsizkan M, Ulutin C, Gunhan O. Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma. Neuropathology 2008;28(01):29–34	Turkey	54	Glioblastoma	IV	Immunohistochemistry	Hazard ratio	None	6
EI-Sayed and Taha (2011)⁴³43 El-Sayed M, Taha MM. Immunohistochemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival. Turk Neurosurg 2011;21(01): 27–35	Egypt	26	Glioblastoma	II-IV	Immunohistochemistry	Summary of clinical data	None	5
Myung et al. (2010)⁴⁴44 Myung J, Cho BK, Kim YS, Park SH. Snail and Cox-2 expressions are associated with WHO tumor grade and survival rate of patients with gliomas. Neuropathology 2010;30(03):224–231. Doi: 10.1111/j.1440-1789.2009.01072.x https://doi.org/10.1111/j.1440-1789.2009...	Korea	56	Glioma	I-IV	Tissue microarray	Overall survival/progression-free survival	WHO grade, Snail, treatment, extent of surgery	8
Chen et al. (2012)⁴⁵45 Chen L, Wang X, Wang H, et al. miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer 2012;48(16):3104–3111. Doi: 10.1016/j.ejca.2012. 02.007 https://doi.org/10.1016/j.ejca.2012.02.0...	China	91	Glioma	Not available	Immunohistochemistry	Overall survival	None	6
Wang et al. (2015)⁴⁶46 Wang X, Chen Y, Zhang S, et al. Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis. J Neurooncol 2015;125(02):277–285. Doi: 10.1007/s11060-015-1919-6 https://doi.org/10.1007/s11060-015-1919-...	China	76	Glioblastoma	Not available	Immunohistochemistry	Overall survival	Age, gender, 5-LO, Ki-67, p53, EI	8
Zhang et al. (2017)⁴⁷47 Zhang F, Chu J, Wang F. Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas. Oncol Lett 2017;14(02):1303–1308	China	70	Glioma	I-IV	Immunohistochemistry	Overall survival	None	6

[1] Address for correspondence Lili Zou (e-mail: zoulili@ctgu.edu.cn).

Brasil

Brasil

Significância clinicopatológica e prognóstica da COX-2 em pacientes com glioma: uma metanálise

Resumo

Introdução

Objetivo

Métodos

Resultados

Conclusão